Blood glucose monitoring device and method, and storage medium

Abstract

The invention provides blood glucose monitoring equipment, a blood glucose monitoring method and a storage medium. A blood glucose monitoring method according to the present disclosure includes measuring a glucose concentration of a subcutaneous tissue fluid of a user through a probe, transmitting the glucose concentration measured by the probe to a processor through a transponder, correcting the glucose concentration based on one or more of a first correction value, a second correction value, and a third correction value, and determining a blood glucose level of the subcutaneous tissue fluid. The first correction value is related to a production batch of the probe, the second correction value is related to a blood glucose monitoring history of the user, and the third correction value is related to a blood glucose value measured by the user through the blood during the measurement of the glucose concentration by the probe.

Description

Technical Field

[0001] The present invention relates to a blood sugar monitoring device, method and storage medium. Background Art

[0002] Diabetes is one of the most common metabolic diseases, and its prevalence rate is increasing year by year. China is the country with the largest number of diabetes patients. The 2021 International Diabetes Federation (IDF) map shows that the number of diabetes patients in China has reached 140 million, but the awareness rate, treatment rate, and compliance rate are all less than half. The threat posed by diabetes and its complications to people's health has become a health problem that cannot be ignored. Good blood sugar control is the cornerstone of diabetes treatment, which helps delay the occurrence of complications and improve patient prognosis.

[0003] Blood glucose monitoring is an important part of diabetes management. The results of blood glucose monitoring help assess the degree of glucose metabolism disorder in diabetic patients, develop reasonable blood glucose-lowering plans, follow up changes in the condition, and guide adjustments to treatment plans.

[0004] Self-monitoring of blood glucose (SMBG) by patients is the basic form of blood glucose monitoring, and glycosylated hemoglobin (HbA1c) is the gold standard for reflecting the average level of long-term blood glucose control. However, both HbA1c and SMBG have certain limitations. HbA1c reflects the average blood glucose level in the past 2-3 months, so there is a "delayed effect" on the blood glucose assessment of treatment. At the same time, HbA1c is difficult to reflect the characteristics of blood glucose fluctuations in patients, and cannot accurately reflect the risk of hypoglycemia in patients. SMBG cannot accurately reflect the fluctuations in blood glucose throughout the day, and multiple measurements will also increase patient discomfort.

[0005] Therefore, continuous glucose monitoring technology (CGM) has become an effective supplement to traditional blood glucose monitoring methods and has gradually been promoted and applied in clinical practice. Compared with traditional blood glucose monitoring methods, CGM can continuously measure the patient's blood glucose and reflect the patient's blood glucose status in various living and treatment states such as rest, eating, exercise, and medication. As a CGM-related indicator, the normal blood glucose range time (time in range, TIR) has gradually become one of the important indicators for evaluating blood glucose.

[0006] CGM is a technology that detects changes in glucose concentration in the interstitial fluid of the subcutaneous tissue through a glucose sensor. Compared with finger blood glucose monitoring, CGM can provide more comprehensive blood glucose information, understand the trend of blood glucose fluctuations, and detect high and low blood glucose that are not easily detected by traditional monitoring methods. It has been increasingly used in clinical practice.

[0007] However, there is a certain difference between the blood glucose value obtained by CGM and the venous blood glucose value. Therefore, a solution for obtaining the blood glucose value more accurately and in real time is desired. Summary of the invention

[0008] According to one aspect of an embodiment of the present disclosure, a blood glucose monitoring method is provided, comprising: measuring the glucose concentration of a user's subcutaneous tissue fluid through a probe, sending the glucose concentration measured by the probe to a processor through a repeater, and correcting the glucose concentration based on one or more of a first correction value, a second correction value, and a third correction value to obtain an estimated blood glucose value of the user, wherein the first correction value is related to a production batch of the probe, the second correction value is related to the user's blood glucose monitoring history, and the third correction value is related to the blood glucose value of the user measured through blood during the period when the probe measures the glucose concentration.

[0009] According to the method of an embodiment of the present disclosure, the first correction value is obtained by the following items: obtaining one or more glucose concentrations of subcutaneous tissue fluid measured by each probe in a probe set including the probe, wherein the probes in the probe set are in the same or adjacent production batches, obtaining one or more blood glucose values ​​corresponding to the one or more glucose concentrations, obtaining one or more first deviations based on the one or more glucose concentrations and the one or more blood glucose values, and determining the average value of the one or more first deviations as the first correction value.

[0010] According to the method of an embodiment of the present disclosure, the second correction value is obtained by: obtaining one or more glucose concentrations of subcutaneous tissue fluid measured by a historical probe used by the user, obtaining one or more blood glucose values ​​corresponding to the one or more glucose concentrations, obtaining one or more second deviations based on the one or more glucose concentrations and the one or more blood glucose values, and determining the average value of the one or more second deviations as the second correction value.

[0011] According to the method of an embodiment of the present disclosure, the third correction value is obtained by: measuring one or more glucose concentrations of the user's subcutaneous tissue fluid by the probe to obtain one or more blood glucose values ​​corresponding to the one or more glucose concentrations; obtaining one or more third deviations based on the one or more glucose concentrations and the one or more blood glucose values; setting corresponding weights for the one or more third deviations based on the measurement order of the blood glucose values ​​corresponding to the one or more third deviations; and determining the third correction value based on the one or more third deviations and the corresponding weights.

[0012] According to the method of an embodiment of the present disclosure, the one or more glucose concentrations are discrete values ​​in time, and wherein obtaining one or more third deviations comprises: fitting the one or more glucose concentrations based on time to obtain a fitted glucose concentration, obtaining one or more blood glucose values, obtaining one or more fitted glucose concentrations corresponding to the one or more blood glucose values ​​in time based on the time of the one or more blood glucose values, and obtaining one or more third deviations based on the one or more blood glucose values ​​and the one or more fitted glucose concentrations.

[0013] According to the method of an embodiment of the present disclosure, setting corresponding weights for one or more third deviations includes: setting increasing weights for one or more third deviations according to the measurement order of blood glucose values ​​corresponding to the one or more third deviations from front to back.

[0014] According to the method of an embodiment of the present disclosure, setting corresponding weights for one or more third deviations includes: in response to one or more third deviations including one third deviation, setting the weight of the one third deviation to 100%; in response to one or more third deviations including two third deviations, setting the weights of the two third deviations to 22% and 78%, respectively, wherein the blood glucose value corresponding to the third deviation with the weight set to 22% is measured before the blood glucose value corresponding to the third deviation with the weight set to 78%; in response to one or more third deviations including three third deviations, setting the weights of the three third deviations to 9%, 20%, and 71%, respectively, wherein the blood glucose value corresponding to the third deviation with the weight set to 9% is measured before the blood glucose value corresponding to the third deviation with the weight set to 20%. The blood glucose value corresponding to the third deviation with the weight set to 9% is measured before the blood glucose value corresponding to the third deviation with the weight set to 20%, and the blood glucose value corresponding to the third deviation with the weight set to 20% is measured before the blood glucose value corresponding to the third deviation with the weight set to 71%; in response to one or more third deviations including more than three third deviations, the weights of the last three third deviations measured among the more than three third deviations are set to 9%, 20%, and 71%, respectively, and the weights of the remaining third deviations are set to 0%, wherein the blood glucose value corresponding to the third deviation with the weight set to 9% is measured before the blood glucose value corresponding to the third deviation with the weight set to 20%, and the blood glucose value corresponding to the third deviation with the weight set to 20% is measured before the blood glucose value corresponding to the third deviation with the weight set to 71%.

[0015] According to the method of an embodiment of the present disclosure, the time interval between the measurement times of the blood glucose values ​​corresponding to the one or more third deviations does not exceed 144 hours.

[0016] According to the method of an embodiment of the present disclosure, it also includes: setting weights for the first correction value, the second correction value, and the third correction value, respectively, determining a comprehensive correction value based on the weights and the first correction value, the second correction value, and the third correction value, and obtaining an estimated blood glucose value of the user based on the comprehensive correction value and the glucose concentration measured by the probe.

[0017] The method according to an embodiment of the present disclosure further includes calculating a glycated hemoglobin value based on the estimated blood glucose value.

[0018] The method according to an embodiment of the present disclosure also includes determining the probability of a user developing cardiovascular complications of diabetes based on one or more of the following: the age at which the user is diagnosed with diabetes, the user's gender, whether the user smokes, the glycated hemoglobin value, the systolic blood pressure, and the low-density cholesterol value.

[0019] According to the method of the embodiment of the present disclosure, the probe is mechanically connected to the transponder by one or more of magnetic attraction and bonding.

[0020] According to one aspect of an embodiment of the present disclosure, a blood glucose monitoring device is provided, comprising: a transponder configured to receive a glucose concentration of a user's subcutaneous tissue fluid measured by the probe from a probe and send the glucose concentration to a processor; and the processor configured to: receive the glucose concentration from the transponder, correct the glucose concentration based on one or more of a first correction value, a second correction value, and a third correction value to obtain an estimated blood glucose value of the user, wherein the first correction value is related to a production batch of the probe, the second correction value is related to the user's blood glucose monitoring history, and the third correction value is related to a blood glucose value of the user measured through blood during the period when the probe measures the glucose concentration.

[0021] According to one aspect of an embodiment of the present disclosure, a computer-readable storage medium is provided, on which computer-executable instructions are stored, and when the instructions are executed by a processor, they are used to implement any of the methods described above.

[0022] According to an aspect of an embodiment of the present disclosure, a computer-readable storage medium is provided, on which computer-executable instructions are stored. When the instructions are executed by a processor, the method according to claim 13 is implemented.

[0023] According to an embodiment of the present disclosure, a blood glucose monitoring device, method, and storage medium can correct the glucose concentration of subcutaneous tissue fluid to obtain accurate blood glucose values ​​in real time. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The above and other aspects, features and advantages of certain embodiments of the present disclosure will become more apparent from the following description in conjunction with the accompanying drawings, in which:

[0025] Figure 1 A blood glucose monitoring device according to an embodiment of the present disclosure is shown.

[0026] Figure 2 A blood glucose monitoring method according to an embodiment of the present disclosure is shown.

[0027] Figure 3A-3D A schematic diagram showing components of a blood glucose monitoring device according to an embodiment of the present disclosure

[0028] Figure 4 A non-transitory computer-readable storage medium according to an embodiment of the present disclosure is shown. DETAILED DESCRIPTION

[0029] Before proceeding to the following detailed description, it may be advantageous to set forth definitions of certain words and phrases used throughout this disclosure. The terms "include" and "comprising" and their derivatives mean including, but not limited to. The phrase "at least one," when used with a list of items, means that different combinations of one or more of the listed items may be used, and only one item in the list may be required. For example, "at least one of A, B, C" includes any of the following combinations: A, B, C, A and B, A and C, B and C, A and B and C.

[0030] Definitions for other specific words and phrases are provided throughout this disclosure. Those of ordinary skill in the art should understand that in many, if not most instances, such definitions apply to prior and future uses of such defined words and phrases.

[0031] The various embodiments of the principles of the present disclosure in this patent application document are described below in conjunction with the accompanying drawings for illustration only, and should not be interpreted as limiting the scope of the present disclosure in any way. It will be appreciated by those skilled in the art that the principles of the present disclosure can be implemented in any appropriately arranged system or device. In some cases, the actions described in the present disclosure can be performed in different orders, and the desired results can still be achieved. In addition, the process depicted in the accompanying drawings does not necessarily require the specific order shown or the sequential order to achieve the desired results. In a specific embodiment, multitasking and parallel processing may be advantageous.

[0032] The text and drawings are provided as examples only to help understand the present disclosure. They should not be interpreted as limiting the scope of the claims attached to the present disclosure in any way. Throughout the drawings, the same reference numerals generally indicate the same elements. Although certain embodiments and examples have been provided, based on the contents of the present disclosure, it is clear to those skilled in the art that the embodiments and examples shown may be changed without departing from the scope of the present disclosure.

[0033] Diabetes management is currently a difficult point in chronic disease management, involving diet, exercise, drug therapy, diabetes education and monitoring of metabolic indicators, especially blood sugar.

[0034] The application of dynamic blood glucose monitoring sensor probes can more comprehensively reflect blood sugar fluctuations and reduce the pain caused by finger blood measurement. It is one of the important means of blood sugar monitoring at this stage and is also accepted by more and more patients. However, the data monitored by users themselves may have a certain lag. For example, users may measure dynamic blood sugar values ​​for a period of time (several days) and extract the measured dynamic blood sugar values ​​after completing the measurement. Therefore, it may not be possible to communicate with medical care in a timely manner. For diabetic patients with poor blood sugar control, hospitalization is often recommended, and insulin intensive treatment is performed when necessary. During hospitalization, on the one hand, blood sugar can be monitored multiple times for patients to adjust the hypoglycemic plan in time, and on the other hand, it makes communication between doctors and patients more timely, and changes in patients' conditions can be detected in time. However, many patients may not be convenient for hospitalization due to personal reasons such as work and family, and hospitalization also increases the workload of hospitals and medical staff.

[0035] In order to more accurately adjust the blood sugar lowering plan for diabetic patients, it is necessary to monitor the patient's blood sugar data in real time and communicate with them in a timely manner.

[0036] Figure 1 FIG. 2 shows a blood glucose monitoring device according to an embodiment of the present disclosure. Figure 1 As shown, the blood glucose detection device 100 may include a repeater 110, a processor 120, and an optional probe 130. The probe 130, the repeater 110, and the processor 120 may be arranged at different locations, for example, the probe 130 and the repeater 110 may be arranged at the user's body, and the processor 110 may be arranged in the user's electronic device.

[0037] The repeater 110 may be configured to receive the glucose concentration of the user's subcutaneous tissue fluid measured by the probe from the probe and send the glucose concentration to the processor. The probe may be configured in the blood glucose monitoring device 100 or may be configured independently of the blood glucose monitoring device 100. The repeater 110 may include one or more communication devices. The repeater 110 may be connected to the processor via a communication device such as Bluetooth. TM ,Bluetooth TMThe processor 120 may communicate with the probe 130 using a short-range communication protocol of LE, sub GHz, wireless HART, infrared link, ZigBee, radio frequency identification (RFID), WiFi, the Internet, the World Wide Web, an intranet, a virtual private network, a wide area network, a local area network, a private network using a communication protocol that is proprietary to one or more companies, Ethernet, and HTTP, as well as various combinations of the foregoing, thereby forwarding the glucose concentration from the probe 130 to the processor 120 in real time. The transponder 110 may be mechanically connected between the probe and the transponder by one or more of a magnetic attraction method and an adhesive method.

[0038] The processor 120 may be configured to receive the glucose concentration from the repeater 110. That is, the processor 120 may receive the glucose concentration of the user's subcutaneous tissue fluid measured by the probe 130 via the repeater 110. The processor 120 may be configured in the user's electronic device, for example, the processor 120 may be configured in the user's mobile phone or other electronic device. The processor 120 may be a central processing unit (CPU), a digital signal processor (DSP), a graphics processing unit (GPU), or other forms of processing units with data processing capabilities and / or program execution capabilities, such as a field programmable gate array (FPGA), an electronic controller (ECU), a microcontroller unit (MCU), etc. The processor 120 may be a general-purpose processor or a dedicated processor. Generally, the glucose concentration in the subcutaneous tissue fluid is positively correlated with the venous blood glucose. By measuring the glucose concentration in the subcutaneous tissue fluid, the venous blood glucose value may be estimated. The processor 120 may calibrate the glucose concentration measured by the probe 130 based on a plurality of correction values ​​to estimate the user's blood glucose value. According to an embodiment of the present disclosure, the processor 120 may calibrate the glucose concentration based on one or more of the first correction value, the second correction value, and the third correction value to obtain the user's estimated blood glucose value. Among them, the first correction value is related to the production batch of the probe, the second correction value is related to the user's blood glucose monitoring history, and the third correction value is related to the blood glucose value measured by the user through the blood during the period when the probe measures the glucose concentration. One or more applications can be run in the processor 120, and the application can upload the estimated blood glucose value to the cloud, thereby realizing three-terminal data sharing among physicians, case managers, and users such as patients. In addition, the application can synchronize the user's estimated blood glucose value to the hospital information system (HIS) or guardian in the hospital, and can issue an alarm when the estimated blood glucose is significantly abnormal, providing assistance for the precise management of diabetic patients.

[0039] The optional probe 130 can be configured to measure the glucose concentration of the user's subcutaneous tissue fluid. According to an embodiment of the present disclosure, the probe 130 can be attached to the user's skin in an adhesive manner. According to an embodiment of the present disclosure, the probe 130 can include one or more glucose sensors. For example, the one or more glucose sensors include a glucose sensor based on enzyme electrode technology, a glucose sensor based on microdialysis technology, a glucose sensor based on surface plasmon resonance technology, and a glucose sensor based on infrared spectroscopy technology. The probe 130 can send the measured glucose concentration of the subcutaneous tissue fluid to the repeater 110.

[0040] Figure 2 FIG. 2 shows a blood glucose monitoring method according to an embodiment of the present disclosure. Figure 2 As shown, the blood glucose monitoring method may include steps S210, S220, and S230.

[0041] In step S210, the glucose concentration of the user's subcutaneous tissue fluid may be measured by the probe. For example, the probe may be attached to the user's skin, and the glucose concentration of the user's subcutaneous tissue fluid may be measured by a glucose sensor included in the probe.

[0042] In step S220, the glucose concentration measured by the probe may be sent to the processor via the repeater. The repeater may obtain the glucose concentration from the probe and send the glucose concentration to the processor.

[0043] In step S230, the glucose concentration can be corrected based on one or more of a first correction value, a second correction value, and a third correction value to obtain an estimated blood glucose value of the user, wherein the first correction value is related to a production batch of the probe, the second correction value is related to the blood glucose monitoring history of the user, and the third correction value is related to a blood glucose value measured by the user through the blood during the period when the probe measures the glucose concentration.

[0044] According to an embodiment of the present disclosure, the first correction value may be related to the production batch of the probe currently in use. The probe may be marked with a serial number, and the serial number may be related to the production batch indicating the production date, production location, etc. of the probe. Probes with serial numbers that differ by a certain number (such as but not limited to 1000, etc.) may be determined as a probe set. In this way, the probes in the probe set may be in the same or adjacent production batches. The probes in the probe set may have the same and similar measurement performance. For example, according to an embodiment of the present disclosure, one or more glucose concentrations of subcutaneous tissue fluid measured by each probe in the probe set including the probe may be obtained. For example, the probes in the probe set may be used by one or more users, and the probes in the probe set may measure the glucose concentration of the subcutaneous tissue fluid of the one or more users. In an embodiment of the present disclosure, one or more blood glucose values ​​corresponding to one or more glucose concentrations are obtained. For example, one or more users may each measure one or more blood glucose values ​​through blood (e.g., venous blood or fingertip blood). One or more blood glucose values ​​may correspond to one or more glucose concentrations, respectively. For example, the blood glucose value and the glucose concentration corresponding thereto may correspond to the same user and the same time. According to an embodiment of the present disclosure, one or more first deviations may be obtained based on one or more glucose concentrations of one or more users at one or more times and one or more corresponding blood glucose values. For example, the difference between the blood glucose value and the corresponding glucose concentration may be determined as the first deviation. The average value of the one or more first deviations may be determined as the first correction value.

[0045] According to an embodiment of the present disclosure, the second correction value may be related to the user's blood glucose monitoring history. According to an embodiment of the present disclosure, one or more glucose concentrations of subcutaneous tissue fluid measured by a historical probe that the user has used can be obtained. For example, the user may have used multiple probes and may be configured to obtain one or more glucose concentrations measured by the user using the historical probe. According to an embodiment of the present disclosure, when the user uses the historical probe to measure one or more glucose concentrations of subcutaneous tissue fluid, the user may measure one or more blood glucose values ​​through blood (e.g., venous blood or fingertip blood). One or more blood glucose values ​​corresponding to one or more glucose concentrations may be obtained. One or more blood glucose values ​​may correspond to one or more glucose concentrations, respectively. For example, the blood glucose value and the glucose concentration corresponding thereto may correspond to the same probe and the same time. According to an embodiment of the present disclosure, one or more second deviations may be obtained based on one or more glucose concentrations and one or more blood glucose values. For example, the difference between the blood glucose value and the glucose concentration corresponding thereto may be determined as the second deviation. The average value of one or more second deviations may be determined as the second correction value.

[0046] According to an embodiment of the present disclosure, the third correction value may be related to the blood glucose value measured by the user through the blood during the period when the probe measures the glucose concentration. According to an embodiment of the present disclosure, the user may use the probe to measure one or more glucose concentrations, and the one or more glucose concentrations measured by the probe may be discrete values ​​in time. For example, the probe may measure the glucose concentration in the tissue fluid once every certain time period (such as 1 minute, 5 minutes, or longer or shorter). According to an embodiment of the present disclosure, during the period when the user uses the current probe to measure the glucose concentration in the subcutaneous tissue fluid, the user may measure one or more blood glucose values ​​corresponding to the one or more glucose concentrations through blood (for example, venous blood or fingertip blood). For example, the blood glucose value and the glucose concentration corresponding thereto may correspond to the same user, the same probe, and the same time. The discrete one or more glucose concentrations measured by the probe may be fitted based on time to obtain a fitted glucose concentration. For example, the discrete one or more glucose concentrations may be fitted based on a smooth fitting algorithm to obtain a fitting curve, and the fitting curve may be tangent to the discrete one or more glucose concentrations. One or more fitting glucose concentrations corresponding to the one or more blood glucose values ​​in time may be obtained based on the measurement time of the one or more blood glucose values. According to an embodiment of the present disclosure, one or more third deviations may be obtained based on one or more glucose concentrations and one or more blood glucose values. For example, one or more third deviations may be obtained based on one or more blood glucose values ​​and one or more fitted glucose concentrations. For example, the difference between the blood glucose value and the fitted glucose concentration corresponding thereto may be determined as the third deviation. Corresponding weights may be set for one or more third deviations to determine the third correction value based on one or more third deviations and corresponding weights. According to an embodiment of the present disclosure, corresponding weights may be set for one or more third deviations based on the measurement sequence of the blood glucose values ​​corresponding to the one or more third deviations. For example, increasing weights may be set for one or more third deviations according to the measurement sequence of the blood glucose values ​​corresponding to the one or more third deviations from front to back. For example, a third deviation obtained by measuring blood glucose values ​​older or earlier (e.g., farther from the current in time) may be given a higher weight than a third deviation obtained by measuring blood glucose values ​​newer or later (e.g., closer to the current in time).

[0047] According to an embodiment of the present disclosure, the one or more third deviations include one third deviation. That is, when the user measures the glucose concentration of the interstitial fluid through one probe, the user can measure the blood glucose value once through the blood, thereby obtaining one third deviation. In response to the one or more third deviations including only one third deviation, the weight of the one third deviation can be set to 100%.

[0048] According to an embodiment of the present disclosure, one or more third deviations include two third deviations. That is, the user can measure the blood glucose value twice through blood when measuring the glucose concentration of the tissue fluid through a probe, thereby obtaining two third deviations. In response to the one or more third deviations including two third deviations, the weights of the two third deviations can be set to 22% and 78%, respectively. As described above, a higher weight can be set for the third deviation obtained by the blood glucose value measured later. That is, the blood glucose value corresponding to the third deviation with a weight set to 22% can be measured before the blood glucose value corresponding to the third deviation with a weight set to 78%.

[0049] According to an embodiment of the present disclosure, one or more third deviations include three third deviations. That is, the user can measure the blood glucose value three times through blood while measuring the glucose concentration of tissue fluid through a probe, thereby obtaining three third deviations. In response to the one or more third deviations including three third deviations, the weights of the three third deviations can be set to 9%, 20%, and 71%, respectively. As described above, a higher weight can be set for the third deviation obtained by the blood glucose value measured later. That is, the blood glucose value corresponding to the third deviation with a weight set to 9% can be measured before the blood glucose value corresponding to the third deviation with a weight set to 20%, and the blood glucose value corresponding to the third deviation with a weight set to 20% can be measured before the blood glucose value corresponding to the third deviation with a weight set to 71%.

[0050] According to an embodiment of the present disclosure, one or more third deviations include more than three third deviations. That is, the user can measure more than three blood glucose values ​​through blood when measuring the glucose concentration of tissue fluid through a probe, thereby obtaining more than three third deviations. In response to one or more third deviations including more than three third deviations, the weights of the three third deviations measured last among the more than three third deviations can be set to 9%, 20%, 71%, respectively, and the weights of the remaining third deviations can be set to 0%. That is, when calculating the third correction value, only the three third deviations calculated by the three blood glucose values ​​measured last can be considered, while the third deviation calculated by the previously measured blood glucose value can be ignored. As described above, a higher weight can be set for the third deviation obtained by the later measured blood glucose value. That is, the blood glucose value corresponding to the third deviation with a weight set to 9% can be measured before the blood glucose value corresponding to the third deviation with a weight set to 20%, and the blood glucose value corresponding to the third deviation with a weight set to 20% can be measured before the blood glucose value corresponding to the third deviation with a weight set to 71%.

[0051] According to an embodiment of the present disclosure, the time interval between the measurement times of the blood glucose values ​​corresponding to the one or more third deviations may not exceed 144 hours.

[0052] According to an embodiment of the present disclosure, weights may be set for the first correction value, the second correction value, and the third correction value, respectively, and a comprehensive correction value may be determined based on the weights and the first correction value, the second correction value, and the third correction value. The comprehensive correction value may be determined by the following equation (1):

[0053] (1)

[0054] Wherein, Cs is the comprehensive correction value, C1 is the first correction value, C2 is the second correction value, and C3 is the third correction value. The initial value of a% can be 5%, and the initial value of b% can be 20%. After the probe reaches the usage limit, the Gaussian kernel model L2 constrained least squares learning method can be used to fit again, and then the optimal ratio of a%, b% can be estimated, so that the sum of a%, b% is not greater than 15%.

[0055] The estimated blood sugar value of the user can be obtained based on the comprehensive correction value and the glucose concentration measured by the probe. For example, the comprehensive correction value and the glucose concentration measured by the probe can be summed to obtain the estimated blood sugar value. The glycated hemoglobin value (eHbA1c) and the glucose management indicator (GMI) can be further calculated based on the estimated blood sugar value obtained by the blood sugar detection device 100.

[0056] According to an embodiment of the present disclosure, the probability of the user developing cardiovascular complications of diabetes can be further determined based on the glycated hemoglobin value. For example, the q factor of the user developing cardiovascular complications of diabetes can be determined according to the following equation (2):

[0057] (2)

[0058] Among them, q is the q factor, age at diagosis value is the age at which diabetes is diagnosed; for the sex value, female is 1 and male is 0; for the smoker value, smoker is 1 and non-smoker is 0; HbA1c is the glycated hemoglobin value; bpsys is the systolic blood pressure value; LDL is the low-density lipoprotein cholesterol value.

[0059] The probability of a user developing cardiovascular complications of diabetes within 10 years can be calculated based on equation (3):

[0060] (3)

[0061] Where risk% is the probability of the user developing cardiovascular complications of diabetes within 10 years, and q is the q factor calculated by equation (2).

[0062] Figure 3A-3D A schematic diagram showing components of a blood glucose monitoring device according to an embodiment of the present disclosure is shown.

[0063] like Figure 3A A schematic diagram of a transponder is shown. The transponder can be mechanically connected to the probe by bonding or magnetic attraction. Figure 3B A metal ring is shown, which can be connected to the probe in a snap-on manner, and an adhesive can be attached to one side of the metal ring, which is connected to the transponder through the adhesive. In this way, the reliability of the connection between the transponder and the probe can be further strengthened. Figure 3C A charging cradle is shown, via which the transponder can be charged. Figure 3D A charging cable is shown, by which the charging base can be connected to a power source to charge the transponder.

[0064] Figure 4 A non-transitory computer-readable storage medium according to an embodiment of the present disclosure is shown.

[0065] like Figure 4 As shown, a non-transitory readable storage medium 400 stores computer instructions 410 , which, when executed by a processor, perform one or more steps of the various methods and additional aspects thereof as described above.

[0066] Exemplarily, the non-transitory readable storage medium 400 may be any combination of one or more computer-readable storage media, for example, a computer-readable storage medium contains program codes for executing the above-mentioned various methods.

[0067] Exemplarily, when the program code is read by a computer, the computer may execute the program code stored in the computer storage medium to implement, for example, one or more steps of the above-mentioned various methods and additional aspects thereof according to at least one embodiment of the present disclosure.

[0068] Exemplarily, the non-transitory readable storage medium may include a memory card of a smart phone, a storage component of a tablet computer, a hard disk of a personal computer, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM), a portable compact disk read-only memory (CD-ROM), flash memory, and other non-transitory readable storage media or any combination thereof.

[0069] According to the blood glucose monitoring device, method, and storage medium of the embodiments of the present disclosure, accurate blood glucose values ​​can be obtained in real time by correcting the glucose concentration of subcutaneous tissue fluid.

[0070] Although the present disclosure has been described with exemplary embodiments, various changes and modifications may be suggested to one skilled in the art. The present disclosure is intended to encompass such changes and modifications as fall within the scope of the appended claims.

[0071] Any description in the present invention should not be construed as implying that any particular element, step, or function is an essential element that must be included in the claims scope. The scope of the patented subject matter is limited solely by the claims.

Claims

1. A blood glucose monitoring method, comprising: The probe measures the glucose concentration of the user's subcutaneous tissue fluid. The glucose concentration measured by the probe is sent to a processor via a transponder, correcting the glucose concentration based on one or more of the first correction value, the second correction value, and the third correction value to obtain an estimated blood sugar value of the user, The first correction value is related to the production batch of the probe, the second correction value is related to the blood glucose monitoring history of the user, and the third correction value is related to the blood glucose value measured by the user through the blood during the period when the probe measures the glucose concentration.

2. The method according to claim 1, wherein: The first correction value is obtained by: obtaining one or more glucose concentrations of subcutaneous tissue fluid measured by each probe in a probe set including the probe, wherein the probes in the probe set are in the same or adjacent production batches, obtaining one or more blood glucose values ​​corresponding to one or more glucose concentrations, obtaining one or more first deviations based on one or more glucose concentrations and one or more blood glucose values, An average value of the one or more first deviations is determined as a first correction value.

3. The method according to claim 1, wherein: The second correction value is obtained by: obtaining one or more glucose concentrations of subcutaneous tissue fluid measured by a historical probe used by the user, obtaining one or more blood glucose values ​​corresponding to one or more glucose concentrations, obtaining one or more second deviations based on the one or more glucose concentrations and the one or more blood glucose values, An average value of the one or more second deviations is determined as a second correction value.

4. The method according to claim 1, wherein: The third correction value is obtained by: measuring one or more glucose concentrations of the user's subcutaneous tissue fluid by the probe, obtaining one or more blood glucose values ​​corresponding to one or more glucose concentrations, obtaining one or more third deviations based on the one or more glucose concentrations and the one or more blood glucose values, Based on the measurement order of the blood glucose values ​​corresponding to the one or more third deviations, setting corresponding weights for the one or more third deviations, A third correction value is determined based on the one or more third deviations and corresponding weights.

5. The method according to claim 4, wherein: The one or more glucose concentrations are discrete values ​​in time, and wherein obtaining the one or more third deviations comprises: fitting one or more glucose concentrations based on time to obtain a fitted glucose concentration, obtaining one or more blood glucose values, obtaining one or more fitted glucose concentrations corresponding to the one or more blood glucose values ​​in time based on the time of the one or more blood glucose values, One or more third deviations are obtained based on the one or more blood glucose values ​​and the one or more fitted glucose concentrations.

6. The method according to claim 4, wherein: Setting corresponding weights for one or more third deviations includes: According to the measurement order from front to back of the blood glucose values ​​corresponding to the one or more third deviations, increasing weights are set for the one or more third deviations.

7. The method according to claim 6, wherein: Setting corresponding weights for one or more third deviations includes: In response to the one or more third deviations including one third deviation, setting a weight of the one third deviation to 100%; In response to the one or more third deviations including two third deviations, setting weights of the two third deviations to 22% and 78%, respectively, wherein the blood glucose value corresponding to the third deviation with the weight set to 22% is measured before the blood glucose value corresponding to the third deviation with the weight set to 78%; In response to the one or more third deviations including three third deviations, weights of the three third deviations are set to 9%, 20%, and 71%, respectively, wherein the blood glucose value corresponding to the third deviation with the weight set to 9% is measured before the blood glucose value corresponding to the third deviation with the weight set to 20%, and the blood glucose value corresponding to the third deviation with the weight set to 20% is measured before the blood glucose value corresponding to the third deviation with the weight set to 71%; In response to one or more third deviations including more than three third deviations, the weights of the last three third deviations measured among the more than three third deviations are set to 9%, 20%, and 71%, respectively, and the weights of the remaining third deviations are set to 0%, wherein the blood glucose value corresponding to the third deviation with the weight set to 9% is measured before the blood glucose value corresponding to the third deviation with the weight set to 20%, and the blood glucose value corresponding to the third deviation with the weight set to 20% is measured before the blood glucose value corresponding to the third deviation with the weight set to 71%.

8. The method according to claim 6, wherein: The time interval between the measurement times of the blood glucose values ​​corresponding to the one or more third deviations does not exceed 144 hours.

9. The method according to claim 1, further comprising: weights are set for the first correction value, the second correction value, and the third correction value, respectively. determining a comprehensive correction value based on the weight and the first correction value, the second correction value, and the third correction value, An estimated blood sugar value of the user is obtained based on the integrated correction value and the glucose concentration measured by the probe.

10. The method of claim 1, further comprising calculating a glycated hemoglobin value based on the estimated blood glucose value.

11. The method of claim 1 , further comprising determining a probability of the user developing cardiovascular complications of diabetes based on one or more of: The age at which the user was diagnosed with diabetes, User gender, Whether the user smokes, Glycated hemoglobin value, Systolic blood pressure, and Low density cholesterol value. 12 . The method according to claim 1 , further comprising mechanically connecting the probe to the transponder by one or more of magnetic attraction and bonding.

13. A blood glucose monitoring device, comprising: a transponder configured to receive the glucose concentration of the user's subcutaneous tissue fluid measured by the probe from the probe and send the glucose concentration to a processor; as well as The processor is configured to: receiving the glucose concentration from the transponder, correcting the glucose concentration based on one or more of the first correction value, the second correction value, and the third correction value to obtain an estimated blood sugar value of the user, The first correction value is related to the production batch of the probe, the second correction value is related to the blood glucose monitoring history of the user, and the third correction value is related to the blood glucose value measured by the user through the blood during the period when the probe measures the glucose concentration.

14. A computer-readable storage medium having computer-executable instructions stored thereon, wherein the instructions are used to implement the method according to any one of claims 1 to 12 when executed by a processor.

Images